Gelteq Limited Ordinary Shares (GELS)vsViatris Inc (VTRS)
GELS
Gelteq Limited Ordinary Shares
$0.57
-1.67%
HEALTHCARE · Cap: $5.97M
VTRS
Viatris Inc
$16.89
+0.24%
HEALTHCARE · Cap: $19.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 3123533% more annual revenue ($14.74B vs $471,800). GELS leads profitability with a 0.0% profit margin vs -2.8%. VTRS earns a higher WallStSmart Score of 48/100 (D+).
GELS
Avoid33
out of 100
Grade: F
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GELS.
Margin of Safety
-85.6%
Fair Value
$8.69
Current Price
$16.89
$8.20 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 48.9% year-over-year
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -24.9% — below average capital efficiency
4.9% revenue growth
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : GELS
The strongest argument for GELS centers on Price/Book, Revenue Growth. Revenue growth of 48.9% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bear Case : GELS
The primary concerns for GELS are EPS Growth, Market Cap, Profit Margin.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.
Key Dynamics to Monitor
GELS profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.
GELS is growing revenue faster at 48.9% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VTRS scores higher overall (48/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gelteq Limited Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. The company is headquartered in Caulfield, Australia.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?